SecBot SecBot
8-K ·Filed Nov 5, 2026

COGT

Cogent Biosciences, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed11d 10h ago SEC0001193125-26-449926
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key catalyst is the GIST PDUFA date on Nov 30, 2026, just 25 days away. Approval would trigger a commercial launch and potential revenue inflection. Monitor FDA decision and any advisory committee activity.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Cogent Biosciences reported Q3 2026 net loss of $111.4M, wider than the $80.9M loss in Q3 2025, driven by increased R&D and G&A spending ahead of potential FDA approvals. The company maintains a $791.1M cash balance sufficient into late 2028, with three PDUFA dates approaching: GIST (Nov 30, 2026), NonAdvSM (Dec 30, 2026), and AdvSM (June 29, 2027). No revenue or EPS consensus beat/miss is applicable as the company is pre-revenue.

Key Facts

  • Net loss of $111.4M in Q3 2026 vs $80.9M in Q3 2025
  • Cash, cash equivalents and marketable securities of $791.1M as of Sep 30, 2026
  • R&D expenses $75.1M in Q3 2026 vs $69.0M in Q3 2025
  • G&A expenses $42.1M in Q3 2026 vs $14.4M in Q3 2025
  • PDUFA date for bezuclastinib in GIST: November 30, 2026
  • PDUFA date for bezuclastinib in NonAdvSM: December 30, 2026
  • PDUFA date for bezuclastinib in AdvSM: June 29, 2027
  • Cash runway expected into late 2028, past all three PDUFA dates

Financial Impact

Net loss widened by $30.5M YoY to $111.4M; cash burn $1.2M QoQ (from $792.3M to $791.1M)

net losscash positionR&D expensesG&A expenses

Risk Factors

  • FDA non-approval or delay for bezuclastinib in GIST, NonAdvSM, or AdvSM
  • Widening net losses and increasing operating expenses without revenue
  • Competition from approved therapies (avapritinib, imatinib, sunitinib)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-449926
Document: cogt-20261105.htm0001193125-26-449926
Document: 0001193125-26-449926-index-headers.html0001193125-26-449926
Document: 0001193125-26-449926-index.html0001193125-26-449926
Document: 0001193125-26-449926.txt0001193125-26-449926
8-K Data (Synthetic)0001193125-26-449926

Track record

13 reports on COGT

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing No price data
  3. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
  4. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  5. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  6. Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
  7. Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  8. Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
  9. May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
  10. May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026